Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1

Reuters

06/25

Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1

Mira Pharmaceuticals Inc. $(MIRA)$ has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2546217559"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546217559\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546217559?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-25 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546217559","market":"fut","top_or_hot":-1,"title":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mira Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/MIRA\">$(MIRA)$</a> has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-25 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mira Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/MIRA\">$(MIRA)$</a> has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRA","symbol_name":"Mira Pharma","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL99FqMP:1","article_id":"2546217559","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546217559","pubTimestamp":1750852827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1. Mira Pharmaceuticals Inc.  has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRA":"Mira Pharma","BK4007":"制药"},"translate_title":"Mira Pharmaceuticals Inc.正在等待监管部门批准收购SKNY Pharmaceuticals，旨在通过SKNY-1彻底改变减肥和戒烟市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRA":0.9},"content_text":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n    \n\n        Mira Pharmaceuticals Inc. $(MIRA)$ has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}